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Neurons display important differences in plasma membrane composition between
somatodendritic and axonal compartments, potentially leading to currently unexplored
consequences in G-protein-coupled-receptor signaling. Here, by using highly-resolved
biosensor imaging to measure local changes in basal levels of key signaling components,
we explored features of type-1 cannabinoid receptor (CB1R) signaling in individual axons
and dendrites of cultured rat hippocampal neurons. Activation of endogenous CB1Rs
led to rapid, Gi/o-protein- and cAMP-mediated decrease of cyclic-AMP-dependent protein
kinase (PKA) activity in the somatodendritic compartment. In axons, PKA inhibition was
significantly stronger, in line with axonally-polarized distribution of CB1Rs. Conversely,
inverse agonist AM281 produced marked rapid increase of basal PKA activation in
somata and dendrites, but not in axons, removing constitutive activation of CB1Rs
generated by local production of the endocannabinoid 2-arachidonoylglycerol (2-AG).
Interestingly, somatodendritic 2-AG levels differently modified signaling responses to
CB1R activation by 9 -THC, the psychoactive compound of marijuana, and by the
synthetic cannabinoids WIN55,212-2 and CP55,940. These highly contrasted differences
in sub-neuronal signaling responses warrant caution in extrapolating pharmacological
profiles, which are typically obtained in non-polarized cells, to predict in vivo responses
of axonal (i.e., presynaptic) GPCRs. Therefore, our results suggest that enhanced
comprehension of GPCR signaling constraints imposed by neuronal cell biology may
improve the understanding of neuropharmacological action.
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INTRODUCTION
Polarized neuronal architecture maintains the directionality of
information flow through neuronal networks. Accordingly, pro-
tein and lipid composition of the plasma membrane greatly
differs between axons and the somatodendritic compartment
(Horton and Ehlers, 2003). Local interaction between cell mem-
brane components is increasingly considered as a key dynamic
component in sensory and signaling pathways. Notably, the
highly regulated lipid environment may control the structure,
conformation and function of embedded proteins (Phillips et al.,
2009). A major brain G-protein coupled receptor (GPCR) that
may be particularly sensitive to the lipid composition of the
plasma membrane is the type-1 cannabinoid receptor (CB1R).
Predominantly localized in axons and specific presynaptic nerve
terminals, CB1R is the neuronal target of endocannabinoid lipids
(eCBs) and of 9-tetrahydrocannabinol (THC), the major psy-
choactive substance ofmarijuana. CB1Rsmay show elevated tonic
(constitutive) activation in neurons (Pertwee, 2005), potentially
resulting from a combined effect of conformational instability
(D’Antona et al., 2006) and ubiquitously present membrane-
borne eCBs, such as 2-arachidonoylglycerol (2-AG), which is the
most prominent brain eCB (Alger and Kim, 2011; Howlett et al.,
2011) as well as an important intermediate in the production
of several other bioactive lipids (Nomura et al., 2011). 2-AG
is released from cell membrane phospholipids by the action of
phospholipase C and diacylglycerol lipases (DAGLα and DAGLβ).
eCBs are generally considered to be retrograde signals, being pro-
duced in the postsynaptic cell and traveling “backwards” across
the synaptic cleft to activate CB1Rs on presynaptic nerve termi-
nals (Freund et al., 2003; Kano et al., 2009). However, in addition
to this retrograde synaptic signaling effect, eCBs synthetized in
the somatodendritic membrane may also have cell-autonomous
effects on local CB1Rs, such as endocannabinoid-mediated soma-
todendritic slow self-inhibition (SSI) (Bacci et al., 2004; Marinelli
et al., 2009) or somatodendritic endocytosis-driven transcytotic
targeting (Leterrier et al., 2006; Simon et al., 2013). These findings
suggest that locally produced 2-AG may activate somatodendritic
CB1Rs, although such CB1R-induced somatodendritic signaling
has not yet been shown directly.
CB1R activation, through coupling to Gi/o heterotrimeric pro-
teins, leads to inhibition of cyclic adenosine monophosphate
(cAMP) production and inhibition of cyclic-AMP-dependent
protein kinase (PKA) activity (Howlett, 2005). cAMP and
PKA regulate essential biological functions in neurons such
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as excitability, efficacy of synaptic transmission and axonal
growth/pathfinding. Therefore, CB1R coupling to this major sig-
naling pathway may have important consequences on neuronal
function. However, in absence of direct measurement of soma-
todendritic and axonal CB1R signaling, whether and how dif-
ferences in local CB1R density and local 2-AG content regulate
signaling responses to cannabinoids remain unknown.
More generally, it is currently not known how the highly-
polarized neuronal membrane environment may shape GPCR
signaling. This information may be important to better under-
stand neuronal effects of therapeutic or abused drugs. Indeed,
pharmacological response profiles are usually established in non-
polarized heterologous expression systems, such as immortalized
cell lines, but results derived from these experimental setups may
not precisely indicate the pharmacological response that the stud-
ied ligand will elicit in polarized neuronal environments, for
instance in the extremely thin axons. Therefore, here we used a
highly-resolved and sensitive Förster Resonance Energy Transfer
(FRET) approach to measure in vitro ligand-induced modulation
of basal cAMP/PKA levels downstream of endogenous CB1Rs,
in individual axons, dendrites, and somata of well-differentiated
hippocampal neurons.
MATERIALS AND METHODS
ANIMALS
All experiments were performed in agreement with the
European Community Council Directive of 22nd September 2010
(010/63/UE) and the local ethics committee (Comité d’éthique en
matière d’expérimentation animale n◦59, C2EA – 59, ‘Paris Centre
et Sud’) were used for dissociated cell culture experiments.
CHEMICALS, ANTIBODIES AND DNA CONSTRUCTS
CB1R agonists WIN55,212,2 (WIN), CP55,940 (CP) and 2-
arachydonoylglycerol (2-AG), CB1R inverse agonist AM281
(AM) and DAGL inhibitor RHC80267 (RHC) were obtained
from R&D Systems Europe. Dimethyl Sulfoxide (DMSO),
Tetrahydrolipstatin (THL), 9-Tetrahydrocannabinol solution
(THC), Pertussis Toxin (PTX), Forskolin (Fsk), monoclonal
mouse anti-Tau antibody, monoclonal mouse anti-microtubule-
associated protein 2 (anti-MAP2) antibody, Bovine Serum
Albumin (BSA) and Poly-D-Lysine were obtained from SIGMA-
ALDRICH. Polyclonal anti-DAGLα antibody was obtained from
Frontier Institute co., ltd (JAPAN). B27, Lipofectamine 2000 and
Neurobasal were obtained from Life Technologies.
AKAR4, Lyn-AKAR4 and AKAR4-Kras probes were pro-
vided by Dr. Jin Zhang’s laboratory (Baltimore, USA). TEpacVV
probe provided by Dr. Kees Jalink laboratory (Amsterdam,
Netherlands).
HIPPOCAMPAL NEURONAL CULTURES
Hippocampal neuronal cultures were performed essentially as
described previously (Leterrier et al., 2006). Briefly, hippocampi
of Sprague–Dawley rat (Janvier) embryos were dissected at
embryonic day 18. After trypsinization, dissociation was achieved
with a fire-polished Pasteur pipette. Cells were counted and
plated on poly-D-lysine-coated 18-mm diameter glass coverslips,
at a density of 300–400 cells/mm2. The plating medium was
Neurobasal supplemented with 2% B27 and containing Stabilized
Glutamine (0.5mM) and penicillin G (10U/ml)/streptomycin
(10 g/ml). Four hours after plating, the coverslips were transferred
into Petri dishes containing supplemented Neurobasal medium
that had been conditioned for 24 h on a 80% confluent glia
layer. Neurons were transfected after 6 days in vitro (DIV6) using
Lipofectamine 2000, following the manufacturer’s instructions.
FRET IMAGING
Neurons transfected either with TEpacVV or AKAR4-Kras probes
were imaged by videomicroscopy between DIV7 and DIV11 on
a motorized Nikon Eclipse Ti-E/B inverted microscope with the
Perfect Focus System (PFS) in a 37◦C thermostated chamber,
using an oil immersion CFI Plan APO VC 60X, NA 1.4 objective
(Nikon).
Acquisitions were carried out at the excitation wavelength
of the CFP (434 ± 15 nm) using an Intensilight (Nikon).
Emitted light passed through an Optosplit II beam-splitter (Cairn
Research) equipped with a FF509-FDi01 dichroïc mirror, a FF01-
483/32-25 CFP filter and a FF01-542/27-25 YFP filter and was
collected by an EM-CCD camera (Evolve 512, Photometrics),
mounted behind a 2× magnification lens. Acquisitions were per-
formed by piloting the set-up with Metamorph 7.7 (Molecular
Devices). All filter sets were purchased from Semrock.
Cultured neurons on 18-mm coverslips were placed in a closed
imaging chamber containing an imaging medium: 120mMNaCl,
3mM KCl, 10mM HEPES, 2mM CaCl2, 2mM MgCl2, 10mM
D-glucose, 2% B27, 0.001% BSA.
We have previously characterized axons and dendrites in our
cultures by using immunolabeling for Tau and MAP2 proteins,
respectively, that allowed to establish the characteristic morphol-
ogy of these neurites in cultured hippocampal neurons. Here
we have used this morphological criteria to identify axons and
dendrites. The acquisition lasted 90min, recording one image
each 2min, by imaging in parallel 25–30 [10 à15 neurones
mais pour chaque neurone: 1 champs sur soma, 1 champ sur
l’axone et une champ sur dendrites distales (facultatif)] fields-
of view on the same coverslip. 30min after the beginning of the
acquisition, pharmacological treatment was applied then 60min
after the beginning of the acquisition, Forskolin 10μM was
applied.
FRET DATA ANALYSIS
All imaged neurons were analyzed and included in the final result,
except the neurons that matched at least one of the three pre-
defined exclusion criteria: (1) lack of response to the terminal Fsk
stimulation, (2) loss of focus during the time-lapse sequence, or
(3) the impossibility to realign artifactual lateral movement. All
key analysis results were obtained by an experimenter blind to the
treatment condition.
Images were divided in two parts in ImageJ to separate the
CFP channel from the YFP channel. Stacks were realigned to cor-
rect for artifactual lateral movement. Data were then analyzed on
Matlab by calculating the FRET ratio at each time point for one or
several Regions Of Interest (ROIs). The user defined ROIs for each
position. For each image, the value of the FRET ratio corresponds
to IC−BCIY−BY for
TEpacVV probe and to IY−BYIC−BC for AKAR4-Kras probe
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IY: Mean Intensity of ROI in YFP channel;
BY: Mean Intensity of the background in YFP channel;
IC: Mean Intensity of ROI in CFP channel;
BC: Mean intensity of the background in CFP channel
For each ROI, the FRET ratio was then normalized by the
baseline mean, defined as the 7 time points before first treatment
application.
FRET Ratio normalized to baseline= 100 ∗ Rc−RoRo
Rc: Value of raw FRET ratio
Ro: Mean of the baseline
The quantitative results obtained for each neuronal compart-
ment were grouped together and, for each time point, the mean
FRET ratio normalized to baseline and S.E.M. were calculated.
Due to CFP photobleaching, FRET ratio tends to increase slowly
during the acquisition. This deviation was corrected for somata
and dendrites on Matlab. Mean slope was calculated for all neu-
rons in somata and dendrites, respectively, for the last 7 time
points before addition of treatment and substracted from all
FRET ratio time points. In the axon, precise execution of this cor-
rection is not possible. Indeed, as the signal-to-noise ratio is lower
in the extremely thin axons as compared to somata and dendrites,
the bleaching is “hidden” in the noise, hindering the precise estab-
lishment of the correction slope. Thus, we did not correct for CFP
photobleaching in the axon.
FRET STATISTICAL ANALYSIS
FRET Response was obtained by calculating the mean FRET ratio
in Matlab for 6 time points after treatment, from +4 to +14min
(Response).
Groups were compared using GraphPad Prism. Significance
of differences between various conditions was calculated using
unpaired t-tests or one-way ANOVA with Newman-Keuls post-
tests for computing p estimates. NS p > 0.05, ∗p < 0.05, ∗∗p <
0.01 and ∗∗∗p < 0.001.
IMMUNOCYTOCHEMISTRY
DIV9 hippocampal cultured neurons were briefly rinsed with
Dulbecco’s PBS (DPBS; PAA laboratories) and fixed in DPBS
containing 4% paraformaldehyde and 4% sucrose. After perme-
abilization with a 5min incubation in DPBS containing 0.1%
Triton X-100 and blocking for 30min in antibody buffer (DPBS
supplemented with 2%BSA and 3%normal goat serum), neurons
were incubated with primary antibodies diluted 1:200 (DAGLα)
or 1:250 (MAP2 and Tau) in antibody buffer for 1 h at room tem-
perature. After DPBS rinses, neurons were labeled with secondary
antibodies 1:400 in antibody buffer for 30min at room temper-
ature. Coverslips were fixed with Mowiol containing Hoechst.
Images were obtained using a dry 40× objective lens on Zeiss
Axio Imager M1. Excitation wavelengths of 488 nm (DAGLα) and
568 nm (MAP2 or Tau) were used.
CONFOCAL MICROSCOPY
Hippocampal cultured neurons were cotransfected at DIV6
with DsRed2 and various FRET probes (TEpacVV, AKAR4,
AKAR4-Kras, Lyn-AKAR4) and fixed in DPBS containing 4%
paraformaldehyde and 4% sucrose at DIV7. Images were obtained
using an oil immersion objective lens (Plan-Apochromat 60X, NA
1.4) on a Nikon A1 confocal microscope. Excitation wavelengths
of 488 nm (FRET probes) and 568 nm (DsRed2) were used. Stacks
were obtained with one image per optical section and 300 nm
between each section.
RESULTS
ENDOGENOUS CB1Rs MODULATE BASAL PKA ACTIVATION LEVELS IN
NEURONS
The characteristic inhibition of cyclic AMP production and
PKA activity by Gi/o-protein coupled GPCRs is usually detected
in pharmacological assays after GPCR over-expression and
forskolin-induced artificial activation of adenylyl cyclases. Here
we aimed to directly measure cannabinoid-induced changes in
basal levels of neuronal PKA signaling, downstream of endoge-
nous CB1Rs in cultured hippocampal neurons. Pilot experi-
ments indicated that by using a sensitive EM-CCD camera and
hardware-based focus stabilization (see Materials and Methods)
we are able to measure cannabinoid-induced inhibition of cyclic
AMP production and PKA activity in relatively large cytoplas-
mic volumes such as neuronal somata by using the soluble
TEpacVV probe (Klarenbeek et al., 2011) (Figure 1A) and AKAR4
(Depry et al., 2011) (Figure 1B), respectively. However, smaller
diameter neurites such as distal dendrites and axons gave weak
(low amplitude) and highly variable responses, leading to a low
signal-to-noise ratio, which impeded the reliable measure of the
relatively small amplitude cannabinoid-induced changes in the
FRET ratio with the AKAR4 probe. To overcome this experi-
mental limitation, we hypothesized that, since the PKA activator
cAMP is produced by membrane-bound adenylyl cyclases at the
plasma membrane and PKA deactivator phosphodiesterases are
cytosolic (Neves et al., 2008), targeting a PKA probe to the
plasma membrane may strongly increase experimental sensitiv-
ity. Indeed, results of a previous report show both higher FRET
responses and higher PKA-sensitive potassium current responses
downstream of Gs-protein activation in dendrites that have a
high surface-to-volume ratio as compared to the soma (Castro
et al., 2010). Therefore, we expressed separately two membrane-
targeted PKA biosensors: AKAR4-Kras (Depry et al., 2011), which
is targeted to the non-raft domains of the plasma membrane
(Figure 1C), and Lyn-AKAR4 (Depry et al., 2011), which is tar-
geted to the raft regions of the plasma membrane (Figure 1D)
in well-differentiated hippocampal neurons. In our experimen-
tal conditions, AKAR4-Kras showed a more homogenous dis-
tribution that segregated well with the plasma membrane at
different optical sections of the somatodendritic domain, while
Lyn-AKAR4 was more strongly localized to relatively small mem-
brane microdomains and intracellular structures (Figures 1C,D).
In order to focus on plasma-membrane localized endogenous
CB1Rs, further experiments were therefore performed using
AKAR4-Kras.
Does the membrane-targeted AKAR4-Kras probe permit the
measurement of cannabinoid-induced modulation of basal PKA
levels downstream of endogenous CB1Rs in all neuronal sub-
compartments? We tested the sensitivity of our experimental
setup by determining the minimal amount of cytoplasmic vol-
ume necessary to the detection of cannabinoid-induced modu-
lation of basal PKA levels, in individual thin (mean diameter =
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FIGURE 1 | Quantitative measure of basal cAMP/PKA pathway
modulation downstream of endogenous neuronal CB1Rs in small
cytoplasmic volumes. (A–D) Cultured hippocampal neurons expressing
soluble (cytoplasmic) DsRed2 and various FRET probes designed to measure
cAMP concentration or PKA activity: TEpacVV (A), AKAR4 (B), AKAR4-Kras (C),
LYN-AKAR4 (D). After fixation, confocal imaging at two different optical
sections shows sub-cellular localization of the probes. AKAR4-Kras probes are
well-localized to the plasma membrane in the somatodendritic region. (E,F)
Modulation of basal PKA activity downstream of endogenous CB1Rs in axonal
Regions of Interest (ROI) in AKAR4-Kras expressing neurons. The first image of
the acquisition on YFP channel, inverted and with enhanced contrast for better
visibility, is shownwith the ROI (orange) (E,F). Themean FRET ratio is shown at
4min (-t4) before (E1,F1) and at 6min (t6) after (E2,F2) the addition of treatment
at t0. Incubation with vehicle does not change the FRET ratio (E2) compared to
baseline (E1) but addition of agonist WIN 55-212,2 (WIN) 100 nM induces a
rapid FRET-ratio decrease (F2), as compared to baseline (F1). (G) Test of FRET
imaging sensitivity by determining the smallest axonal cytoplasmic volume
allowing the measurement of significant PKA activity decrease after
WIN-induced activation of endogenous CB1Rs. We calculated the mean value
of the FRET response amplitude normalized to baseline (Amp) and its standard
deviation (SD), in different axonal ROIs, between t4 (4min after drug treatment)
and t14. The ratio of the FRET response amplitude to its standard deviation
(Amp/SD) is represented in function of the volume (see text). TheWIN effect is
significantly different from control (modeled as an effect of Amp = 0 with the
same standard deviation than the corresponding WIN-stimulated response) at
the Amp/SD ratio equal to −0.91 (in gray, p < 0.05, Student’s t-test, N = 10),
which is reached starting from ∼1μm3 axonal volume. Data information: Scale
bar: 10μm (A–F).
0.7μm, see Figure 3C) and mature (day in vitro 9—DIV9) axons
of AKAR4-Kras expressing neurons. By using a large region
of interest (ROI) to measure the FRET ratio change, treat-
ment with the synthetic CB1R agonist, WIN55,212-2 (WIN) at
100 nM (Figure 1F), but not with vehicle (Figure 1E), induced
a important change of the FRET ratio within 2min, indicating
that CB1R activation induces a decrease of basal PKA activ-
ity downstream of endogenous CB1Rs. Measuring the FRET
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responses in a single axon by gradually decreasing the size
of the ROI, we determined the minimum cytoplasmic volume
necessary for reliable measurement of the WIN-induced FRET
signal change. ROI volumes have been determined as described
in “Supplementary Materials and Methods.” We found that a
significant decrease of WIN-induced basal PKA activity down-
stream of endogenous CB1Rs could be measured in volumes as
small as 1μm3, which corresponds to 1 femtoliter of axonal cyto-
plasm (Figure 1G), by using amembrane targeted biosensor, such
as AKAR4-Kras, possibly because of the high surface-to-volume
ratio of extremely thin neurites.
In conclusion, this experimental approach enables the mea-
surement of modulation of basal neuronal PKA activation levels,
downstream of an endogenous Gi/o protein coupled receptor, in
extremely small cellular volumes, such as the cytoplasm of mature
axons.
TRANSIENT SOMATODENDRITIC CB1Rs CONSTITUTIVELY INHIBIT THE
cAMP/PKA PATHWAY
Previous ultrastructural analysis of hippocampal neurons has
shown that in the somatodendritic region, the steady-state pres-
ence of endogenous CB1Rs at the plasma membrane is very
low both in vitro (Leterrier et al., 2006) and in vivo (Katona
et al., 1999; Thibault et al., 2013). However, previous studies
have also reported that most axonally targeted CB1Rs accomplish
a transient passage on the somatodendritic plasma membrane
(Leterrier et al., 2006; McDonald et al., 2007; Simon et al., 2013).
Currently, it remains unknown whether somatodendritic CB1Rs
are able to inhibit cAMP/PKA signaling in this neuronal com-
partment. Therefore, we measured modulation of basal soma-
todendritic PKA activity downstream of endogenous CB1Rs and
found that treatment with WIN at 100 nM, but not with vehicle,
induced a moderate decrease of the FRET ratio in individual neu-
rons within a few minutes (Figures 2A,B). To precisely analyze
this WIN-induced response, we compared PKA activity in two
groups of neurons treated either with vehicle or WIN (100 nM)
during 30min, followed by treatment with the adenylyl cyclase
activator Forskolin (Fsk, 10μM) (Figures 2C,D), to induce a sat-
urating level of AKAR phosporylation, as reported previously
(Gervasi et al., 2007). Fsk induced strong somatodendritic PKA
activation with a raw baseline-normalized FRET-ratio increase
between 20 and 30%. This increase is in the expected range,
since activation of AKAR4-Kras in HEK293 cells by addition of
50μM Fsk induced an increase of 8% of the raw FRET Ratio
(Depry et al., 2011). Conversely, activation of CB1Rs with WIN
induced a rapid decrease of basal PKA activity in somata (−2.5 ±
0.4%) and dendrites (−3.2 ± 0.5%), which was significant as
compared to vehicle (somata: 0.1 ± 0.3%, dendrites: −0.2 ±
0.4%) (Figures 2C1,C2,D1,D2). Please note that the measured
2–4% changes of the raw baseline-normalized FRET ratio corre-
spond to 10–20% of the maximal response, which equals typi-
cally to 20–25% elevation of the raw baseline-normalized FRET
ratio, as established by the terminal saturating Fsk treatment.
Given that endogenous CB1Rs are not the only Gαi/o-coupled
GPCRs in hippocampal neurons, mobilization of the cAMP/PKA
pathway in the 10–20% range of the maximal response sug-
gests physiological relevance. Moreover, FRET responses showed
Gaussian distribution pattern (as verified by the normality test),
indicating that hippocampal neurons did not segregate into sub-
populations regarding the effects of CB1R agonist/antagonist
application (Supplementary Figures 1A–C). This is in contrast
to a previous ex-vivo report that studied somatic slow self-
inhibition in cortical neurons, where only a subpopulation of
neurons was responsive to cannabinoid treatment (Marinelli
et al., 2009). The effect of WIN was blocked after overnight
treatment with 100 ng/mL of the Gi/o-protein specific inhibitor
pertussis toxin (PTX) (somata: −0.3 ± 0.2%, dendrites: −1.5 ±
0.3%) as well as after 3 h pre-treatment with 1μM of the CB1R-
specific antagonist/inverse-agonist AM281 (somata: 0.3 ± 0.3%,
dendrites: −1.1 ± 0.5%). Therefore, endogenous CB1Rs, tran-
siently present on the somatodendritic plasma membrane, can
be activated by exogenous cannabinoids and are able to subse-
quently inhibit basal PKA signaling through their coupling to Gi/o
proteins both in somata and dendrites.
We have previously reported that somatodendritic CB1Rs are
constitutively endocytosed because of constitutive receptor acti-
vation, which can be inhibited by pharmacological or genetic
tools (Leterrier et al., 2006; Simon et al., 2013). To investigate
whether CB1Rs also constitutively inhibit cAMP/PKA signal-
ing in the somatodendritic compartment, we applied the CB1R
inverse agonist, AM281 at 100 nM, to neurons expressing AKAR4-
Kras. This treatment led to a rapid and significant increase of
the FRET ratio both in somata and dendrites (somata: 1.3 ±
0.2%, dendrites: 2.0± 0.4%) (Figures 2C1,C2,D1,D2). Therefore,
somatodendritic CB1Rs exert a constitutive inhibition on PKA
activity that is removed by inverse agonist treatment.
Taken together these results indicate that somatodendritic
CB1Rs constitutively inhibit PKA activity through the mobiliza-
tion of Gi/o proteins, which is likely due to the inhibition of
adenylate cyclase and subsequent decrease of cAMP production.
To confirm this mechanism, we directly measured themodulation
of basal somatodendritic cAMP concentration, downstream of
CB1Rs, by using the TEpacVV probe (Klarenbeek et al., 2011). The
activation of endogenous CB1Rs with WIN (100 nM) induced a
rapid and significant decrease of cAMP concentration in somata
(−1.5 ± 0.3%) and dendrites (−2.6 ± 0.6%), while application
of the inverse agonist AM281 at 100 nM led to a rapid and sig-
nificant increase of cAMP concentration both in somata (1.7 ±
0.3%) and dendrites (2.6 ± 0.5%) (Figures 2E,E1,E2,F,F1,F2).
Responses to the final 10μM Fsk treatment are also a slightly
different. However, accurate measure of ligand-induced modifi-
cations of artificial adenylyl cyclase stimulation by Fsk was not
the scope of the present study, where we focused on endogenous
CB1R-induced modification of basal PKA activation levels.
These results show that endogenous CB1Rs exert a constitutive
inhibition on the cAMP/PKA signaling pathway both in somata
and dendrites. In addition, somatodendritic CB1Rs can be further
activated by exogenous cannabinoids leading to a rapid decrease
of cAMP concentration and PKA activity through activation of
Gi/o proteins.
AXONAL CB1R SIGNALING IS DIFFERENT FROM DENDRITIC SIGNALING
Previous studies have found a polarized accumulation of tran-
scytosed CB1Rs on the axonal plasma membrane due to reduced
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FIGURE 2 | Somatodendritic CB1Rs constitutively inhibit the
cAMP/PKA pathway. (A,B) Two representative neurons expressing the
membrane-targeted PKA sensor AKAR4-Kras. The first image of the
acquisition on YFP channel with the ROI is shown (A,B). The mean
FRET ratio in somatic ROIs (orange) is shown at 4min (-t4) before (A1,
B1) and at 6min (t6) after the addition of treatment at t0: Vehicle (A2) or
agonist WIN55-212,2 (WIN) 100 nM (B2). (C–F) Averaged responses of
AKAR4-Kras (C,D) or the cAMP sensor TEpacVV expressing neurons (E,F).
The FRET ratio normalized to baseline was calculated for each neuron
with a time-resolution of 2min, separately in somata and dendrites. The
curves represent mean ± S.E.M. of the FRET ratio for all imaged neurons
at each time point. Addition of agonist WIN 100nM but not of vehicle at
t0 results in rapid FRET ratio decrease while inverse-agonist AM281
100nM (AM) treatment results in increased PKA-activation. At 30min,
adenylyl-cyclase activator Forskolin (Fsk) was added at 10μM, inducing a
saturating increase of the FRET ratio. C1,D1,E1,F1: Zoom between -t14
and t30 of C,D,E,F, respectively, shows significant modulation of basal
PKA activity after activation or blockade of CB1Rs. C2,D2,E2,F2: FRET
responses were calculated as the mean response between t4 and
t14min (shaded zone labeled “Response” on C1,D1,E1,F1), using data
normalized to the baseline (shaded zone between -t14 and -t2, labeled
“Baseline” on C1,D1,E1,F1), as described in the Materials and Methods
Section. Implication of Gi/o-proteins was shown by the specific inhibitor
pertussis toxin (PTX), applied overnight at 100 ng/mL before the beginning
of the experiment. The WIN effect was CB1R-induced as shown by
pre-treatment with the CB1R-specific antagonist AM281 (1μM 3h before
the beginning of the experiment). Data information: Data are expressed
as mean ± S.E.M.; Statistical analysis was realized with one-way ANOVA
followed by Newmann-Keuls post-test; NS p > 0.05, ∗p < 0.05,
∗∗p < 0.01, ∗∗∗p < 0.001. Scale bar: 10μm (A,B).
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internalization levels as compared to dendrites (Leterrier et al.,
2006; McDonald et al., 2007; Simon et al., 2013). We asked
whether the recruitment of signaling pathways downstream
of CB1Rs in axons also differ from somata and dendrites.
Application of 100 nM WIN led to a rapid and significant
decrease of basal PKA activity in axons (−14.6 ± 1.4%) com-
pared to vehicle (−1.8 ± 0.6%) (Figures 3A,A1,A2). This effect
was blocked by pre-treatment with AM281 1μM (−2.6 ± 1.0%)
and PTX 100 ng/mL (−5.5 ± 1.1%), showing that PKA inhibition
is specifically mediated by CB1Rs acting through Gi/o pro-
teins. In addition, CB1R activation decreased PKA activity more
strongly in the axon than in dendrites (dendrite response nor-
malized to vehicle: −3.1 ± 0.5%, axonal response normalized to
vehicle: −12.8 ± 1.4) (Figure 3B). Interestingly, in contrast to
dendrites, application of the inverse agonist AM281 at 100 nM
did not induce a detectable change of PKA activity in the axon
(0.1 ± 0.8%), suggesting that axonal CB1Rs are not constitutively
activated (Figures 3A,A1,A2).
Why does axonal CB1R activation lead to a significantly higher
amplitude of PKA inhibition in axons than in dendrites and
somata? First, similarly to their distribution in vivo (Katona
et al., 2001; Bodor et al., 2005; Thibault et al., 2013), CB1Rs
display an axonally polarized distribution in cultured neurons
(Coutts et al., 2001; Leterrier et al., 2006; McDonald et al.,
2007; Simon et al., 2013). Second, theoretical models predict,
and experiments show that, for signaling molecules produced at
the plasma membrane and degraded in the cytoplasm, such as
cAMP, the ratio of the surface area of the plasma membrane to
the cytoplasmic volume [surface/volume ratio (S/V)] becomes
important (Neves et al., 2008). As such, we asked whether the
strong decrease of PKA activity observed after CB1R activation
in the axon is related to the high S/V ratio of this compart-
ment. However, for both axons and distal dendrites, we found
no correlation between neurite diameter and FRET response
amplitude after CB1R activation (Pearson’s correlation coeffi-
cient: rdistal dendrites = −0.065 and raxons = 0.03649) (Figure 3C).
Moreover, a sub-population of distal dendrites has the same
diameter range as axons. In these thin dendritic segments, the
amplitude of the FRET response after CB1R activation was
again significantly different from the axonal response (dendrites
normalized to vehicle:−4.0 ± 0.8%, axons normalized to vehicle:
−12.8 ± 1.4) (Figure 3D). Therefore, morphological differences
between axons and dendrites do not explain the observed signal-
ing disparity among these two compartments, suggesting that the
polarized distribution of neuronal CB1Rs is the main reason for
the enhanced agonist response in axons.
CONSTITUTIVE ACTIVATION OF SOMATODENDRITIC CB1Rs REQUIRES
LOCAL SYNTHESIS OF ENDOCANNABINOIDS
Next we investigated why CB1Rs are constitutively activated in
the somatodendritic compartment but not in the axon, by focus-
ing on the contribution of endocannabinoids, which play an
important role in basal CB1R activation in several experimental
systems (Turu et al., 2007; Howlett et al., 2011). The major endo-
cannabinoid 2-arachidonoylglycerol (2-AG) is a lipid molecule
present in the cell plasma membrane and is synthesized by DAG
Lipases (DAGL). DAGLα, the major DAGL in the postnatal brain,
is segregated to axonal tracts during embryonic development
but was shown to accumulate after birth in the somatodendritic
plasma membrane in several brain areas, such as the cerebel-
lum (Bisogno et al., 2003), striatum (Uchigashima et al., 2007),
hippocampus (Katona et al., 2006; Yoshida et al., 2006) and amyg-
dala (Yoshida et al., 2011). Similarly, we found a somatodendritic
segregation of DAGLα in fully-polarized (DIV9) cultured hip-
pocampal neurons, while no labeling was found in the axon
(Figures 4A,A1). This indicates local production of 2-AG in the
plasma membrane of the somatodendritic compartment but not
in the axonal counterpart. To investigate whether such polarized
2-AG production may explain the aforementioned differences
in constitutive CB1R activation between dendrites and axons,
we pre-treated neurons expressing the AKAR4-Kras probe with
the DAGL inhibitors, Tetrahydrolipstatin (THL) or RHC80267
(RHC), during 3 h before treatment with the inverse agonist
AM281 100 nM (Figures 4B,B1,C,C1). The FRET ratio did not
increase in these neurons after adding AM281, neither in somata
(AM281: 1.6 ± 0.3%, vehicle: 0.2 ± 0.3%, AM281 after THL
1μM: 0.4 ± 0.3%, AM281 after RHC 25μM: 0.1 ± 0.3%) nor in
dendrites (AM281: 2.0 ± 0.5%, vehicle: 0.4 ± 0.4%, AM281 after
THL 1μM: 0.4± 0.3%, AM281 after RHC 25μM:−0.1 ± 0.5%).
Thus, the constitutive inhibition on PKA activity was removed
by DAGL blockade, demonstrating that constitutive activation of
somatodendritic CB1Rs requires locally produced 2-AG.
SIGNALING RESPONSES TO EXOGENOUS LIGANDS WIN, CP55,940
AND9-THC ARE DIFFERENTIALLY SHAPED BY LOCAL PRODUCTION
OF 2-AG IN THE SOMATODENDRITIC COMPARTMENT
Previous results show that, after DAGL inhibition, the amount
of CB1Rs increase on the plasma membrane, both in the soma-
todendritic compartments of neurons and in CHO cells (Turu
et al., 2007). In CHO cells, the elevated CB1R levels at the
plasma membrane yield enhanced G-protein activation follow-
ing WIN administration (Turu et al., 2007). We asked whether
the THL-induced accumulation of CB1Rs on the somatoden-
dritic membrane is able to produce similar enhanced inhibi-
tion of PKA activity after WIN administration, as compared to
basal conditions. Therefore, we pre-treated neurons with THL
(1μM) during 3 h before acquisition and applied WIN during
the FRET acquisition (Figure 5A). Surprisingly, DAGL inhibition
blocked the effect of 100 nM WIN in the somatodendritic com-
partment instead of signaling enhancement (somatic response
to WIN 100nM: −2.4 ± 0.4%, P < 0.01 compared to vehicle
(0.1 ± 0.2%) and P < 0.01 compared to response to WIN
100 nM after 3 h THL 1μM (−0.2 ± 0.6%), one-way ANOVA
followed by Newman-Keuls post-test; dendrite response to WIN
100 nM: −2.8 ± 0.4%, P < 0.01 compared to vehicle (−0.4 ±
0.4%) and P < 0.01 compared to response to WIN 100 nM
after 3 h THL 1μM (−0.6 ± 0.6%), one-way ANOVA followed
by Newman-Keuls post-test) (Figures 5A,A1,C,C1), while it did
not change the FRET response in the axon (response to WIN
100 nM: −14.6 ± 1.1%, P < 0.001 compared to vehicle (−1.9 ±
0.9%) and P > 0.05 compared to WIN 100 nM after 3 h THL
1μM (−12.4 ± 1.2%), one-way ANOVA followed by Newman-
Keuls post-test) (Figures 5A2,C2). This suggests that a local
2-AG production drop, caused by THL pre-treatment, was
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FIGURE 3 | Axonal CB1R signaling differs from dendritic signaling. (A)
Averaged axonal responses of AKAR4-Kras expressing neurons, as shown on
Figures 1E,F. The FRET ratio normalized to baseline was calculated for each
neuron with a time-resolution of 2min. The curves represent mean ± S.E.M.
of the FRET ratio for all imaged neurons at each time point. Addition of
agonist WIN 100nM but not of vehicle or inverse-agonist AM281 100nM
(AM) at t0 results in rapid high-amplitude FRET ratio decrease. At 30min,
adenylyl-cyclase activator Forskolin (Fsk) was added at 10μM, inducing a
saturating increase of the FRET ratio. A1: Zoom between −t14 and t30 of A
shows significant modulation of basal PKA activity after activation of CB1Rs.
A2: FRET responses were calculated as the mean response between t4 and
t14min (shaded zone labeled “Response” on A1), using data normalized to
the baseline (shaded zone between −t14 and −t2, labeled “Baseline” on A1).
Implication of Gi/o-proteins was shown by the specific inhibitor pertussis
toxin (PTX), applied overnight at 100 ng/mL before the beginning of the
experiment. The WIN effect was CB1R-induced as shown by pre-treatment
with the CB1R-specific antagonist AM281 (1μM, 3h before the beginning of
the experiment). (B) Vehicle-normalized FRET response to WIN is
significantly stronger in axons than in dendrites. (C) Individual FRET
responses in axons and distal dendrites are represented in function of their
respective diameter. For each group (distal dendrites and axons), a Pearson
correlation test was calculated showing no correlation between FRET
response and diameter (rdistal dendrites = −0.065 and raxons = 0.03649). (D)
Distal dendrites having the similar diameter than axons still display
significantly weaker vehicle-normalized FRET responses to WIN compared to
axons. Data information: Data are expressed as means ± S.E.M.; Statistical
analysis was realized with one-way ANOVA followed by Newmann-Keuls
post-test (A2) or unpaired t-test (B,D); NS p > 0.05, ∗∗∗p < 0.001.
responsible for the somatodendritic signaling decrease, which
indeed could be rescued by 2-AG (100 nM), applied for 10min
before WIN treatment (somata: −3.3 ± 1.0%, dendrites: −3.7 ±
1.2%, axons: −11.8 ± 1.6%; WIN responses were compared to
vehicle) (Figures 5B,B1,C,C1,C2). By itself, 2-AG used at 1μM
is able to decrease PKA activity in all neuronal compartments,
with a stronger effect in axons as compared to the somatoden-
dritic compartment (somata: −2.6 ± 0.7%, dendrites: −5.5 ±
0.5%, axons: −17.7 ± 1.5%) (Figures 5C,C1,C2). To verify if
the presence of local 2-AG is a general requirement for soma-
todendritic CB1R activation, we tested two other, structurally
different, CB1R agonists: CP55,940 (CP) and 9-THC (THC),
the psychoactive compound of marijuana. In control neurons,
the effect of CB1R activation with 100 nM CP was comparable to
WIN, with a decrease of PKA activity in both dendrites and axons
as well as a stronger amplitude in the axonal response compared
to dendrites (somata: −1.0 ± 0.4%; dendrites: −2.1 ± 0.7%;
axons: −18.4 ± 1.6%) (Figures 5C,C1,C2). However, blockade
of DAGL by THL pretreatment did not decrease the effect of
CP (100 nM) in the somatodendritic compartment. On the con-
trary, and according to our previous expectations for WIN,
this response was enhanced as compared to control neurons
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FIGURE 4 | Constitutive activation of somatodendritic CB1Rs requires
locally synthesized endocannabinoids. (A) Simultaneous immunolabeling
of fully-polarized (DIV9) neurons with anti-DAGLα antibody and either
anti-MAP2 (A) or anti-Tau (A1) antibodies. Large arrows indicate dendrites,
arrow-heads indicate axon and the thin arrow shows an astrocyte. (B,C)
Averaged somatic and dendritic responses of AKAR4-Kras expressing
neurons to inverse-agonist AM281 (AM), with or without inhibiting DAGL
activity. The FRET ratio normalized to baseline was calculated for each neuron
with a time-resolution of 2min. The curves represent mean ± S.E.M. of the
FRET ratio for all imaged neurons at each time point. Addition of 100 nM AM
but not of vehicle at t0 results in elevated PKA activity, revealing constitutive
CB1R activation, which is significantly decreased after DAGL inhibition either
by tetrahydrolipstatin (THL) 1μM or RHC80267 25μM. Data information:
Data are expressed as mean ± S.E.M.; Statistical analysis was realized with
one-way ANOVA followed by Newmann-Keuls post-test; ∗p < 0.05,
∗∗p < 0.01. Scale bar: 20μm (A,A1).
(somata: −5.0 ± 1.2%, dendrites: −5.7 ± 1.3%, axons: −19.2 ±
1.4%; responses to CP 100 nM after 3 h THL 1μM were com-
pared to CP 100 nM alone). Finally, treatment with THC (1μM)
also decreased PKA activity in all neuronal compartments, with
a stronger effect in the axon compared to the somatodendritic
compartment (somata: −1.5 ± 0.4%, dendrites: −2.8 ± 0.5%,
axons: −15.8 ± 2.1%) (Figures 5C,C1,C2). However, the soma-
todendritic effect of 1μM THC was suppressed by THL pre-
treatment while it did not affect the axonal response (somata:
−0.3 ± 0.7%, dendrites: 0.1 ± 1.0%, axons: −14.2 ± 2.5%;
responses to THC 1μM after 3 h THL 1μM were compared
to THC 1μM alone) (Figures 5C,C1,C2). Thus, THC and WIN
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FIGURE 5 | Endogenous 2-AG significantly modifies CB1R responses to
exogenous cannabinoids. (A,B) Averaged somatic, dendritic and axonal
responses of AKAR4-Kras expressing neurons to agonist WIN 55-212,2 (WIN).
The FRET ratio normalized to baseline was calculated for each neuron with a
time-resolution of 2min. The curves represent mean ± S.E.M. of the FRET
ratio for all imaged neurons at each time point. Addition of WIN 100nM but
not of vehicle at t0 results in decreased PKA activity, which effect is
significantly inhibited after DAGL inhibition by tetrahydrolipstatin (THL) 1μM in
somata (A) and dendrites (A1) but not in axons (A2). The effect of THL
pre-treatment on the WIN effect in somata (B) and dendrites (B1) can be
rescued by applying 2-AG at 100 nM 10min before WIN. (C) Variation of
neuronal 2-AG levels (similarly to A,B) modifies the FRET responses to
exocannabinoids WIN55-212,2 100 nM (WIN), CP55,940 100 nM (CP) and
9-THC 1μM (THC), shown as the mean response between t4 and t14min
(shaded zone labeled “Response” on A,B), using data normalized to the
baseline (shaded zone between −t14 and −t2, labeled “Baseline” on A,B) in
somata (C), dendrites (C1) or axons (C2). 2-AG levels were reduced by THL
1μM, applied 3 h before the beginning of the experiment and rescued by
2-AG 100nM at 10min before agonist treatment. Data information: Data are
expressed as mean ± S.E.M.; Statistical analysis was realized with unpaired
t-test (2-AG) or one-way ANOVA followed by Newmann-Keuls post-test (WIN,
CP, and THC); NS p > 0.05, ∗p < 0.05, ∗∗p < 0.01 and ∗∗∗p < 0.001.
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require local presence of 2-AG to activate somatodendritic
CB1Rs.
In conclusion, activation of CB1Rs by exogenous cannabinoids
can have contrasted effects on the mobilization of somatoden-
dritic signaling pathways: these effects are highly shaped by local
presence of 2-AG which is necessary for the effects of both WIN
and THC, but not of CP, in this neuronal compartment.
DISCUSSION
We developed a highly sensitive quantitative in vitro method to
evaluate, for the first time to our knowledge, the modulation of
the cAMP/PKA signaling pathway downstream of an endogenous
Gi/o protein coupled receptor with sub-neuronal resolution. We
measured modulation of basal cAMP/PKA signaling, after activa-
tion or blockade of endogenous CB1Rs, in somata, dendrites and
axons of well-differentiated cultured rat hippocampal neurons.
Our results show that polarized distribution of two neuronal
proteins, the endocannabinoid synthesizing DAGLα enzyme and
the CB1R, leads to previously unappreciated quantitative sub-
domain dependent differences in intraneuronal GPCR signal-
ing. In axons, the combined effect of high CB1R density and
absence of DAGLα activity leads both to elevated response
amplitude following agonist stimulation, as well as to a lack
of constitutive activation. In the somatodendritic compartment,
relatively low CB1R density and high DAGLα activity, locally
producing the membrane component endocannabinoid 2-AG,
results in constitutive activation of CB1R-activated signaling
which is accompanied by significant but relatively low amplitude
agonist-induced signaling responses.
In addition, we show that the 2-AG content of the
somatodendritic plasma membrane has contrasted effects on
CB1R activation by various exogenous cannabinoid ligands:
at the ligand concentrations used in the present study,
CP acts as a classical agonist while both WIN and THC
require the presence of endogenous 2-AG to efficiently activate
CB1Rs.
CB1Rs CONSTITUTIVELY INHIBIT cAMP/PKA SIGNALING IN THE
SOMATODENDRITIC COMPARTMENT BUT NOT IN THE AXON
Several studies reported that CB1Rs display constitutive activity
in neurons (Pan et al., 1998; Hillard et al., 1999) and notably,
these receptors are constitutively endocytosed in the somatoden-
dritic compartment, but not in axons, due to basal activation
(Leterrier et al., 2006; Simon et al., 2013). Here we show that
application of the inverse agonist AM281 leads to a rapid increase
in both somatodendritic cAMP concentration and PKA activity,
suggesting constitutive CB1R activation in the somatodendritic
compartment but not in the axon. In non-polarized cells, con-
stitutive CB1R activity is highly diminished in the absence of
endocannabinoid 2-AG (Turu et al., 2007). We found here that
DAGLα is segregated in the somatodendritic compartment and its
inhibition removes the effect of AM281. Therefore, somatoden-
dritic CB1Rs are constitutively activated by a high-tone of locally
produced 2-AG, and the lack of constitutive activity in the axon is
due to the absence of 2-AG.
Our results show important somatodendritic effects on
cAMP/PKA regulation for an axonal (i.e., presynaptic) receptor.
Previously, CB1R-mediated somatodendritic slow self-inhibition
(SSI) was reported in neocortical interneurons (Bacci et al.,
2004) and pyramidal neurons (Marinelli et al., 2009). During
SSI, activation-induced post-synaptic increase of calcium stim-
ulates somatodendritic DAGL, leading to local 2-AG production
and cell-autonomous activation of somatodendritic CB1Rs and
G protein inwardly rectifying K+ (GIRK) channels (Marinelli
et al., 2008). Our results are coherent with these observations
and extend the mechanical understanding of the phenomenon.
βγ subunits of Gi/o proteins may directly activate GIRK chan-
nels (Lujan et al., 2009). Here we directly demonstrate that
such Gi/o proteins can be activated by CB1Rs in the somato-
dendritic region and we show that this activation impacts on
local cAMP and PKA activation levels. Therefore, it is likely
that SSI-inducing activation leads to a parallel decrease of soma-
todendritic cAMP levels and to PKA inhibition. Interestingly,
while cortical neurons are segregated into sub-populations that
respond differently to CB1R activation ex vivo (Marinelli et al.,
2009), our results, which show a Gaussian distribution in
responses (Supplementary Figure 1), suggest that either such
sub-populations are not present in hippocampal neurons or that
our technique is not sensitive enough to detect such differences.
We also report that basal production of 2-AG is both nec-
essary and sufficient to activate Gi/o proteins through CB1Rs
to achieve measurable constitutive inhibition of somatoden-
dritic cAMP/PKA signaling. GPCRs may also display constitu-
tive activity due to conformational instability (Kenakin, 2004)
and several studies reported that CB1Rs may display consti-
tutive activity in systems apparently free of endocannabinoids
(review in Pertwee, 2005). However, it is difficult to for-
mally exclude the presence of endocannabinoids, since these
lipid molecules may be present in cell plasma membrane at
high levels even in non-stimulated neurons (Alger and Kim,
2011).
Here, our results indicate the complete elimination of mea-
surable constitutive somatodendritic CB1R activation after phar-
macological inhibition of DAGL and the lack of constitutive
activation in the mature axon, where the absence of DAGL sug-
gests low levels of membrane-borne 2-AG. However, a certain
level of conformational instability may be necessary to enable
constitutive activation of CB1R by 2-AG. Alanine substitution
of the T210 residue, which is located in the 3rd transmembrane
helix and is well-conserved in the cannabinoid receptor family but
absent in other class A GPCRs (D’Antona et al., 2006), results in
change of the CB1R conformational state (Simon et al., 2013)
and yields a hypoactive receptor form, which displays signifi-
cantly lower constitutive activity but preserves responsiveness to
agonists (D’Antona et al., 2006). Overexpressed T210A mutant
CB1Rs accumulate on the somatodendritic surface because of
reduced steady-state endocytosis and this accumulation leads to
elevated somatodendritic responses to WIN treatment (Simon
et al., 2013). To further understand the effect of conformational
instability induced by T210 on CB1R signaling, it would be useful
in the future to induce the T210A mutation in the endogenous
CB1R through a genetic editing approach, in order to avoid
the putative effects of receptor overexpression on the signaling
response.
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CB1R ACTIVATION BY EXOGENOUS CANNABINOIDS IN AXONS
DIFFERS FROM THAT IN DENDRITES, WHERE LOCAL 2-AG MODULATES
THE RESPONSE TO AGONISTS
Activation of endogenous CB1Rs leads to a stronger decrease
of PKA activity in axons compared to dendrites. This differ-
ence is not due to the shape of neurites. CB1Rs are enriched
in the axonal plasma membrane, leading to approximately 10-
fold more endogenous CB1Rs receptors at the plasma mem-
brane in axons as compared to dendrites (McDonald et al.,
2007). Here, we observed that the decrease of PKA activity
after CB1R activation is about 3-fold stronger in the axon
than in dendrites. Thus, differences in sub-neuronal signaling
and receptor density are in the same range, suggesting that
the main cause of the polarized signaling response is polar-
ized CB1R distribution. Our previous results have shown that
polarized spatial distribution of CB1Rs is precisely regulated by
steady-state somatodendritic activation and endocytosis coupled
to trans-cytotic targeting (Simon et al., 2013), so it is likely
that polarized distribution (i.e., somatodendritic segregation)
of DAGLα is the principal cause of the polarized distribution
of CB1Rs. However, this model is based on previous data
obtained by using a highly-sensitive quantitative experimen-
tal approach employing overexpressed epitope-tagged CB1Rs
and exogenous cannabinoids (Simon et al., 2013). In future
studies, it would be interesting to verify this hypothesis with
sensitive detection of endogenous CB1R localization and well-
controlled modification of cell-autonomous endocannabinoid
levels.
Our results also indicate that inhibition of 2-AG synthesis pre-
vents WIN-induced activation of CB1Rs in the somatodendritic
compartment, whereas, in the axon, absence of 2-AG leads to a
lack of constitutive activity but does not prevent activation by
WIN. Presently, possible interactions between 2-AG and WIN
on CB1R activation are not clearly understood. CB1R intramem-
brane loops were proposed to shape a “binding pocket” that 2-AG
could reach through a gap allowing lipidic ligands to enter from
membrane bilayer, without need of extracellular access (Hurst
et al., 2013). Aminoalkylindole cannabinoids such as WIN bind
at a different site (McAllister et al., 2003; Hurst et al., 2013), so
WIN could act as a positive allosteric modulator for 2-AG, by
increasing 2-AG-induced constitutive CB1R activation, leading
to enhanced inhibition of cAMP/PKA signaling in the somato-
dendritic compartment. Interestingly, the agonist CP55,940 binds
at a different site than WIN (Kapur et al., 2007) and dissimi-
larly to WIN, CP55,940-mediated inhibition of somatodendritic
PKA activity is significantly stronger after DAGL inhibition. After
DAGL inhibition, CB1R levels increase at the somatodendritic
plasma membrane because of reduced endocytic elimination
(Turu et al., 2007) possibly explaining the enhanced CP effect in
the somatodendritic compartment. In the axon, CP-induced PKA
activity decrease is not modified by THL, as DAGL is absent in
this compartment. Finally, the phytocannabinoid THC induces
a decrease of PKA activity in the somatodendritic compart-
ment that is removed after DAGL inhibition. Therefore, neuronal
pharmacology of THC is similar to WIN but not to CP, suggest-
ing that THC may also act as an exogenous positive allosteric
modulator, that amplifies the CB1R-activating effect of locally
produced 2-AG in the somatodendritic compartment. These sur-
prising interactions between 2-AG and exogenous cannabinoid
ligands may result from changes in CB1R levels on the somato-
dendritic surface but also from different, potentially overlapping
and to date not completely understood mechanisms, such as
conformation-induced changes in ligand affinity and efficiency
and competition for ligand binding sites. Full comprehension
of these effects requires further technical development that,
through enhancing the sensitivity of the experimental approach
presented here, may allow detailed pharmacological character-
ization in the future, such as precise measurement of ligand
affinity and efficacy, of endogenous GPCR signaling in neuronal
sub-domains.
In conclusion, our results show that pharmacological
responses to activation of a major neuronal GPCR are differ-
ent in axons and dendrites. In the somatodendritic compart-
ment, CB1Rs are constitutively activated by locally produced
2-AG, constitutively inhibit the cAMP/PKA pathway and can be
further activated, significantly albeit moderately, by exogenous
cannabinoids. A similar activation profile was reported in non-
polarized cells (Turu et al., 2007). However, the pharmacological
profile of axonal CB1Rs is different: their activation leads to
a strong decrease of PKA activity and no significant constitu-
tive activation is observed. This highly contrasted difference in
sub-neuronal signaling responses warrants caution in extrap-
olating pharmacological profiles, which are typically obtained
in non-polarized cells, to predict in vivo responses of axonal
(i.e., presynaptic) GPCRs. Therefore, the in situ pharmacolog-
ical approach presented in our study may also be useful for
a better understanding of the physiology of other neuronal
GPCRs.
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